Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Neoadjuvant Treatment of Breast Cancer
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- National Institute of Oncology, Hungary
- Target Recruit Count
- 300
- Registration Number
- NCT05131893
- Locations
- 🇭🇺
National Institute of Oncolgy, Budapest, Hungary
Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Institut de cancérologie Strasbourg Europe
- Target Recruit Count
- 20
- Registration Number
- NCT05128617
- Locations
- 🇫🇷
Institut de Cancerologie Strasbourg Europe, Strasbourg, France
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT05116462
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)
- Conditions
- Interventions
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 616
- Registration Number
- NCT05116189
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School-Division of Gynecologic Oncology ( Site 0003), Worcester, Massachusetts, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center ( Site 0007), Hackensack, New Jersey, United States
🇨🇦BC Cancer Victoria ( Site 0513), Victoria, British Columbia, Canada
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05112536
- Locations
- 🇺🇸
UCLA Department of Medicine - Hematology/Oncology, Santa Monica, California, United States
🇺🇸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT05112965
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
🇨🇳Tianjin Cancer Hospital, Tianjin, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, China
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 927
- Registration Number
- NCT05113251
- Locations
- 🇹🇭
Research Site, Khon Kaen, Thailand
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 65
- Registration Number
- NCT05111444
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 98
- Registration Number
- NCT05108870
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
A Study of NX-1607 in Adults With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 345
- Registration Number
- NCT05107674
- Locations
- 🇬🇧
Churchill Hospital, Oxford, United Kingdom
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.